Chronic Myeloid Leukemia

A new drug application for Dasynoc was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Navtemadlin, a novel MDM2 inhibitor, demonstrated potential in treating relapsed or refractory myelofibrosis in the phase 3 BOREAS trial.

Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

The FDA granted priority review to asciminib for the treatment of newly diagnosed, Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia.

The BCR-ABL tyrosine kinase inhibitor TERN-701 has been granted an orphan drug designation from the FDA for the treatment of chronic myeloid leukemia.

The FDA has accepted Xspray Pharma's resubmitted application for Dasynoc, a potential new treatment for chronic myeloid leukemia and acute lymphoblastic leukemia.

Findings from the phase 3 ASC4FIRST trial showed that asciminib demonstrated encouraging major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

A comparison of asciminib and bosutinib demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

A phase 1 trial of TERN-701 for chronic myeloid leukemia plans to start patient screening in December 2023, with initial data expected to be released in the second half of 2024.

During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.

According to Elisabetta Abruzzese, MD, PhD. balancing the care of the mother, the baby, as well disease burden is needed for patients with chronic myeloid leukemia who are pregnant.

There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.

In an interview with Targeted Oncology, Hagop Kantarjian, MD, analyzed the results of the phase 2, OPTIC and PACE trials and explained what these data mean for the future use and administration of ponatinib.

While tyrosine kinase inhibitors the current standard of care for most patients with CML, investigators may need to look at new options and combinations for those with TKI resistance.

Data revealed that a longer time to treatment discontinuation seen with asciminib favored its relative tolerability, correlating with the better-observed safety profile, according to data presented at the International Society for Pharmacoeconomics and Outcomes Research 2022

At the 2022 American Society for Clinical Oncology Annual Meeting, durable responses continued to be shown with asciminib compared with bosutinib in adult patients with chronic myeloid leukemia in chronic phase.

In patients with largely resistant CP-CML, ponatinib showed clinical activity when administered at the 45 mg compared with lower doses.

Two approvals for asciminib were issued by the FDA for the treatment of CML with a Ph+ mutation.

In an interview with Targeted Oncology during the SOHO Annual Meeting, Elisabetta Abruzzese, MD, provided key recommendations for managing pregnancy and chronic myeloid leukemia.

Asciminib for the treatment of 2 chronic myeloid leukemia subgroups is now under FDA consideration for approval.

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.